Chevrolet's pink Corvette Stingray pace car 2026 return. Friday, 30 October, 2026 The Chevy Corvette naturally commands attention, but the exclusive pink-themed racing edition truly captivates onlookers. This distinctive all-pink Corvette serves as one of the brand's most recognizable track vehicles while supporting a crucial mission. Designed to honor the collaboration between Chevrolet and the American Cancer Society, this vehicle helps raise funds through top-driver placements and caution-lap pacing. The Chevrolet and American Cancer Society partnership. Chevrolet's famous pink Corvette is back on the track at premier national raceways. The pink Corvette Stingray serves as the official pace car for NASCAR Cup Series events at Martinsville Speedway and Talladega Superspeedway. This season highlights the 16th consecutive year of Chevrolet collaborating with the American Cancer Society for the "Making Strides Against Breast Cancer" initiative. Beyond a simple sponsorship, Chevrolet actively drives donations across five NASCAR Cup Series races: Charlotte Motor Speedway, Las Vegas Motor Speedway, Phoenix Raceway, Talladega Superspeedway, and Martinsville Speedway. For every top-10 finish by a Team Chevy driver at these events, the brand will contribute $1,500 to the cause, up to a cap of $25,000. Furthermore, Chevrolet will donate $500 for each caution lap led by the pink Corvette at Martinsville or Talladega, for a maximum contribution of $25,000. These generous contributions reflect the brand's ongoing dedication. During the 2025 season, Chevrolet generated over $1.7 million for the campaign, including $32,500 raised directly through the NASCAR program. About the Chevrolet Corvette Stingray. The Chevrolet Corvette Stingray remains a highly athletic sports car built to perform both on and off the circuit. It boasts a muscular V8 engine that delivers rapid acceleration. Drivers can anticipate outstanding road grip, sharp handling, and a remarkably balanced ride. The cabin features adaptable seating that easily transitions from track days to everyday commuting. Additionally, it provides generous cargo volume and premium onboard technology. Contact Husker Chevrolet at Husker Chevrolet to discover more about Chevrolet's signature pink Corvette. Search blog.

ImpediMed appoints Prospective Surveillance pioneer Dr. Nicole stout as Chief Clinical Innovation Officer. October 27, 2026 Nicole L. Stout ImpediMed, a leader in medical technologies for clinically monitoring fluid status and body composition, today announced that Nicole L. Stout, DPT, CLT-LANA, FAPTA, will join the company as Chief Clinical Innovation Officer, effective November 1, 2026. Dr. Stout will lead clinical strategy, research, medical affairs, and key opinion leader engagement, with a focus on accelerating the adoption of the SOZO(R) Digital Health Platform across care settings. An internationally recognized authority in cancer rehabilitation and survivorship, Dr. Stout has spent more than 25 years helping oncology teams identify treatment-related complications early and intervene before they become disabling. She pairs that scientific record with years of experience putting new care models into practice inside health systems. From Evidence to Clinical Practice Dr. Stout's pioneering research helped establish the evidence base for the Prospective Surveillance Model (PSM). The approach pairs pretreatment baseline assessments with risk-stratified interval monitoring, then refers patients to supportive care when changes appear, so care teams can address the physical and functional effects of cancer and its treatment throughout the care continuum. Dr. Stout has designed and implemented surveillance pathways in health systems, resulting in shortened time to intervention for cancer treatment-related conditions and improved clinical operations and service-line performance. She has won support from executive and clinical leaders, then built the business and operational plans that turn new care models into lasting programs. Most recently, as Senior Director of Survivorship and Wellness at the American Cancer Society, Dr. Stout led a national portfolio of programs and initiatives addressing supportive care needs across the cancer continuum. Her earlier clinical, research, and leadership experience includes roles at the West Virginia University Cancer Institute and the NIH Clinical Center. She has also led strategic initiatives involving the National Institutes of Health and the World Health Organization and has published more than 100 peer-reviewed and invited articles on survivorship care delivery. Scaling Prospective Surveillance with SOZO At ImpediMed, Dr. Stout will guide clinical strategies that help health systems accelerate the use of the SOZO Digital Health Platform across the oncology enterprise. The platform is already established in lymphedema assessment. The National Accreditation Program for Breast Centers (NAPBC) Optimal Resources for Breast Care 2027 standards also name bioimpedance spectroscopy (BIS) as a method that meets Standard 5.8, its new lymphedema assessment requirement. In August of 2026, ImpediMed received FDA 510(k) clearance for sarcopenia risk assessment, enabling care teams to use the same scan to monitor muscle loss. Together, they give health systems a foundation for surveillance programs that extend across cancer types and treatment settings. "Nicole brings a rare combination of scientific leadership and a proven ability to translate innovation into clinical practice," said Erik Anderson, Managing Director and Chief Executive Officer of ImpediMed. "She has built surveillance programs, navigated complex health system operations, influenced policy, and earned the trust of leaders across the oncology space for over 25 years. At the top of her career, Nicole is choosing to join this team to help define the next chapter of growth for this company, bringing all of her experience to drive SOZO as a standard of care for cancer survivorship. We couldn't be more excited to welcome Nicole to the team." "I am thrilled to be joining the team at this time. The evidence for early, proactive supportive care is compelling, but real impact depends on what health systems can consistently deliver," said Dr. Stout. "My career has focused on making prospective surveillance practical by connecting objective assessment with clinical workflows, timely intervention, and measurable outcomes. I have been following the SOZO platform and BIS technology over many years, and now is the time to bring together this platform along with my expertise in clinical evidence and implementation to help oncology teams adopt sustainable models of care in cancer survivorship programs." About ImpediMed ImpediMed is a global medical technology company that designs and manufactures bioimpedance spectroscopy (BIS) devices, providing clinicians with real-time insights for personalized patient care. The company's SOZO(R) Digital Health Platform using BIS technology supports noninvasive assessment of fluid status and tissue composition, including applications in cancer-related lymphedema surveillance and sarcopenia risk assessment. The platform also supports structured cancer survivorship and medical weight-management care pathways. For more information, visit www.impedimed.com.

Backed by AAP, West Virginia proposal would allow dental hygienists to give HPV vaccine to 9-year-olds. By Jill Erzen West Virginia health groups are pushing legislation to let dentists and dental hygienists administer the human papillomavirus (HPV) vaccine, West Virginia Watch reported earlier this month. The effort is part of a national push by St. Jude Children's Research Hospital, the American Academy of Pediatrics (AAP) and the American Cancer Society to increase HPV vaccination rates and encourage vaccination starting at age 9. The campaign comes amid questions about the vaccine's safety and claims that it prevents cancer. Merck, the maker of Gardasil, recently agreed to pay $50 million to settle more than 200 lawsuits alleging vaccine-related injuries, including autoimmune disorders and reproductive problems. Although Merck markets Gardasil as a vaccine that protects against certain cancers, clinical trials did not test whether the vaccine prevented cancer - only whether it blocked certain strains of HPV. Merck's Gardasil is the only HPV vaccine available in the U.S. HPV is a common, sexually transmitted virus that most people will encounter during their lives, according to the Centers for Disease Control and Prevention (CDC). Some types can cause cancers, such as cervical or oropharyngeal, which affects the back of the throat. The CDC recommends the shot for children beginning at ages 11-12. In 2021, the U.S. Food and Drug Administration (FDA) approved the HPV vaccine to protect against oropharyngeal cancer - despite no clinical evidence to support the claim. National campaign promotes vaccine-related birthday cards for 9-year-olds The West Virginia Oral Health Coalition is preparing legislation that would allow qualified dental professionals to administer the HPV vaccine. The legislative session begins in January. Similar laws have passed in Kentucky, Indiana, Louisiana, Massachusetts, Mississippi, New Jersey and Oregon. St. Jude's HPV Cancer Prevention Program is working with West Virginia organizations to promote HPV vaccination through dental offices. St. Jude's April and June reports cited the "unique challenges" to vaccination in West Virginia's rural areas, including the spread of "vaccine misinformation" and the "increased value of personal choice" in medical decisions. To encourage earlier vaccination, the American Cancer Society's National HPV Vaccination Roundtable developed a toolkit to help rural dental providers promote the shot. One proposed strategy is sending children birthday cards on their 9th birthdays to encourage parents to discuss HPV vaccination. Merck is also studying whether to extend vaccination to even younger children. The company is funding and conducting clinical trials of Gardasil on children ages 4-8. Lucija Tomljenović, Ph.D., a scientist who has published more than a dozen peer-reviewed papers on HPV vaccination, called the trial "reckless." She said it "assumes safety in an age group in which the vaccine has never been tested." Hygienist said she avoided discussing HPV's sexual transmission The push to expand vaccination through dental offices raises questions not only about safety but also about informed consent - particularly what parents are told about HPV and the vaccine. West Virginia Watch reported that the state conducted a pilot project earlier this year, enlisting dental hygienist Lauren French to discuss HPV vaccination with patients at a rural dental clinic. French said the conversations fit naturally into routine dental visits, which already include oral cancer examinations. However, earlier studies found that dental health providers remain generally reluctant to recommend or administer the vaccine. French acknowledged that her conversations with parents often did not address HPV's sexual transmission. "The way that I go about it is I don't have to bring up sex at all," French told West Virginia Watch. "It's just, 'This is a virus that most people come into contact with.' We want them to get vaccinated before they come into contact with this virus. That's why we suggest age 9 to 16." For parents deciding whether to vaccinate their children, understanding how HPV spreads is part of understanding the purpose and timing of the intervention. Parents also need information about the vaccine's potential risks and the evidence supporting its claimed benefits. Tomljenović has questioned whether Gardasil offers any meaningful protection against cancer, arguing that its risks "clearly outweigh" its benefits. She has also cited research suggesting HPV vaccination may increase cervical cancer risk among women who use oral contraceptives long-term. Other research has raised questions about how vaccination affects HPV types not targeted by the vaccine. A 2023 study in Cell Host & Microbe found the HPV vaccine may actually increase the prevalence and distribution of some HPV virus strains not targeted by the vaccine - including some strains that are linked to cancer. Meanwhile, the CDC convened a workgroup in January 2026 to reexamine HPV vaccination, including its effectiveness, dosing, safety and long-term impact. The FDA's prescribing information for Gardasil lists injection-site pain, swelling and redness, headache, fever, nausea and dizziness among reported adverse reactions. It also warns about fainting and severe allergic reactions. Tomljenović has raised concerns about reports of postural orthostatic tachycardia syndrome (POTS), chronic fatigue syndrome and autoimmune disorders, multiple sclerosis and gynecological problems, including menstrual disorders and infertility. The Defender is 100% reader-supported. No corporate sponsors. No paywalls. Its writers and editors rely on you to fund stories like this that mainstream media won't write. Screenings - which dentists already do - protect against HPV-related cancers A central question in the HPV vaccine debate is how strongly the available evidence supports claims that vaccination prevents cancer. Earlier this year, scientists concluded that two Cochrane reviews - widely cited by health authorities and the media to support the claim that the vaccine reduces cervical cancer incidence by up to 80% - are flawed. The majority of epidemiological studies cited to show the vaccine's effects - including its ability to stop invasive cervical cancer - had serious or critical risk of bias, Tomljenović told The Defender in March, calling the review "garbage." Tomljenović also argued that while Gardasil doesn't prevent HPV-related cancer, routine screenings are essential to reducing deaths from the disease. She pointed to the U.S. cervical cancer death rate of approximately two per 100,000 women as evidence of the importance of screening. The AAP notes on its HealthyChildren.org site that "unlike cervical cancer, there is no test to screen for oral cancer or any other HPV-associated cancer." Even so, dentists already examine patients for signs of oral cancer during routine visits. The Mayo Clinic and Cleveland Clinic describe oral cancer examinations as part of routine dental care. Dentists look for suspicious lumps, sores, red or white patches and other abnormalities. They may refer patients for further evaluation or biopsy when they find something concerning. "During every routine cleaning, there's an exam... And we're telling the patient, 'We're doing an oral cancer screening just to make sure there's no lumps, bumps, or anything that's suspicious in your mouth,'" French told West Virginia Watch.